Usana Health Sciences (USNA) reported $925M in revenue for fiscal 2025, +8.3% year on year. That ranks #1823 by revenue among 2853 SEC filers and #166 in Healthcare. Net income was $10.8M, a net margin of 1.2%. Revenue has declined 0.9% a year on average since 2016 ($1.0B then). The fiscal 2025 balance sheet shows $743M in total assets and $158M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $925M | +8.3% | FY20252026-01-03 |
| Gross profitGrossProfit | $724M | +4.5% | FY20252026-01-03 |
| Operating incomeOperatingIncomeLoss | $37.4M | −43.6% | FY20252026-01-03 |
| Net incomeNetIncomeLoss | $10.8M | −74.4% | FY20252026-01-03 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $22.3M | −63.4% | FY20252026-01-03 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $13.8M | +37.2% | FY20252026-01-03 |
| Total assetsAssets | $743M | −0.7% | FY20252026-01-03 |
| Shareholders' equityStockholdersEquity | $533M | +0.2% | FY20252026-01-03 |
| CashCashAndCashEquivalentsAtCarryingValue | $158M | −12.9% | FY20252026-01-03 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-04-04 | $250M | $7.5M | Open → |
| Q2 20262026-07-04 | $223M | −$21.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Usana Health Sciences Inc
- Ticker
- USNA
- Exchange
- NYSE
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 01-03
- CIK
- 0000896264
Filings
- 10-QAug 13, 2026Open filing →
- 10-QMay 12, 2026Open filing →
- 10-KMar 16, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Madrigal PharmaceuticalsMDGL | $958M | −$288M |
| Pennant GroupPNTG | $948M | $29.6M |
| Ionis PharmaceuticalsIONS | $944M | −$381M |
| Usana Health SciencesUSNA | $925M | $10.8M |
| Tilray BrandsTLRY | $915M | −$121M |
| Inspire Medical SystemsINSP | $912M | $145M |
| Ani PharmaceuticalsANIP | $883M | $78.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Usana Health Sciences — Key figures |url=https://companiesranked.com/en/company/usana-health-sciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Usana Health Sciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/usana-health-sciencesBibTeX
@misc{companiesranked-en-company-usana-health-sciences-2026,
author = {{CompaniesRanked}},
title = {{Usana Health Sciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/usana-health-sciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000896264-26-000021 · March 16, 2026
{{cite web |title=Usana Health Sciences — Key figures — 10-K (0000896264-26-000021) |url=https://www.sec.gov/Archives/edgar/data/896264/000089626426000021/usna-20260103.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-16}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.